Summary
Plasma levels of VM26 were assayed by HPLC in six ovarian cancer patients with normal renal and liver function who received the drugs as an initial 1-h IV infusion of 80 mg/m2 followed by a 24-h IV infusion of 120 mg/m2. These doses and infusion rates were chosen on the basis of mean VM26 clearance values found in a previous study, with the aim of reaching plasma steady-state levels of approximately 6 μg/ml in a short time.
Plasma steady-state levels of 4–10 μg/ml, close to those predicted theoretically, were in fact attained at 4–9 h during the second, slower infusion. Mean half-lives and clearance values were 8.6±1.1 h and 0.78±0.08 l/h/m2. Six percent of the VM26 dose was recovered as unchanged drug in the urines collected up to 24 h after the end of infusion. The glucuronide of VM26 aglycone (4′-demethylepipodophyllotoxin) was identified in the urine of all patients, in amounts corresponding to about 8% of the drug dose.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Benet LZ (1972) General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics. J Pharm Sci 61:536
Boxenbaum HG, Riegelman S, Elashoff RM (1974) Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm 2:123
Broggini M, Colombo T, D'Incalci M (1983) Activity and pharmacokinetics of VM26 in Lewis lung carcinoma-bearing mice. Cancer Treat Rep 67:555
Connors TA, Whisson ME (1966) Cure of mice bearing advanced plasma cell tumours with aniline mustard: The relationship between glucuronidase activity and tumour sensitivity. Nature 210:866
D'Incalci M, Sessa C, Farina P, Rossi C, Beer M, Cavalli F, Masera G, Mangioni C (1982) Clinical pharmacokinetics of VP16. Proc Am Assoc Cancer Res 23:131, abstract 131
D'Incalci M, Rossi C, Sessa C, Urso R, Zucchetti M, Farina P, Mangioni C (1984) Pharmacokinetics of VM26 in ovarian cancer patients. Cancer Treat Rep (in press)
Erba E, Ubezio P, Colombo T, Broggini M, Torti L, Vaghi M, D'Incalci M, Morasca L (1983) Flow-cytometric analysis of DNA distribution after VP16-213 treatment of Lewis lung carcinoma. Cancer Chemother Pharmacol 10:208
Evans WE, Sinkule JA, Crom WR, Dow L, Look AT, Rivera G (1982) Pharmacokinetics of teniposide (VM26) and etoposide (VP 16–213) in children with cancer. Cancer Chemother Pharmacol 7:147
Gibaldi M, Perrier D (1975a) Pharmacokinetics, Dekker, New York, p 50
Gibaldi M, Perrier D (1975b) Pharmacokinetics, appendix 5. Dekker, New York, p 297
Hill BT, Whelan RDH, Rupniak HT, Dennis LY, Rosholt MA (1981) A comparative assessment of the in vitro effects of drugs on cells by means of colony assays or flow microfluorimetry. Cancer Chemother Pharmacol 7:21
Issell BF (1982) The podophyllotoxin derivatives and VP-16 and VM26. Cancer Chemother Pharmacol 7:73
Jardine I, Strife RJ, Kozlowski J (1982) Synthesis, 470-MHz 1H, NMR spectra, and activity of delactonized dervatives of the anticancer drug etoposide. J Med Chem 25:1077
Krishan A, Paika K, Frei E III (1975) Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts. J Cell Biol 66:521
Loike JD (1982) VP16-213 and podophyllotoxin. A study on the relationship between chemical structure and biological activity. Cancer Chemother Pharmacol 7:103
Loike JD, Brewer CF, Sternlicht H, Gensler WJ, Horwitz SB (1978) Structure-activity study of the inhibition of microtube assembly in vitro by podophyllotoxin and its congeners. Cancer Res 38:2688
Rozenczweig H, Von Hoff DD, Henney JE, Muggia F (1977) VM 26 and VP 16-213: A comparative analysis. Cancer 40:334
Sacchi-Landriani G, Guardabasso V, Rocchetti M (1983) NL-FIT: A micro-computer program for non-linear fitting. Comput Programs Biomed 16:35
Stähelin H (1970) 4-Demethyl-epipodophyllotoxin thenylidene glucoside (VM26), a podophyllum compound with a new mechanism of action. Eur J Cancer 6:303
Venditti JM (1971) Treatment schedule dependency of experimentally active antileukemic (L1210) drugs. Cancer Chemother Rep [3] 2:35
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rossi, C., Zucchetti, M., Sessa, C. et al. Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients. Cancer Chemother. Pharmacol. 13, 211–214 (1984). https://doi.org/10.1007/BF00269031
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00269031